Skip to content
easybpt
Browse topics

Physiology

Pathophysiology of Alzheimer disease: amyloid, tau and neurodegeneration

APP processing and the amyloid cascade, tau hyperphosphorylation and Braak staging, the cholinergic and glutamate deficits behind current drugs, genetics (APP, PSEN1, PSEN2, APOE), cerebral amyloid angiopathy and the mechanism of ARIA, and how CSF, plasma and PET biomarkers map onto the 2024 biological definition, with a worked predictive value example for plasma p-tau217.

Tier 2Medical sciences concept

Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made

3 questions9 flashcards

At a glance

  • Alzheimer disease has two defining lesions: extracellular amyloid plaques (amyloid beta peptide) and intracellular neurofibrillary tangles (hyperphosphorylated tau). Synapse and neuron loss follows, beginning in the medial temporal lobe.
  • The amyloid cascade hypothesis holds that amyloid beta accumulation starts a process that drives tau spread, inflammation and neurodegeneration. Amyloid builds up 15 to 20 years before symptoms; tau spread tracks symptoms.
  • The cholinergic deficit explains cholinesterase inhibitors; excess glutamatergic signalling explains memantine. Anti-amyloid antibodies target the upstream lesion.

Loading the rest of the note…

Finished reading?

Test yourself on it:3 questions9 flashcards

Sources

Last updated
14 November 2026
What changed
  • 14 November 2026 Turnstile bot check on sign-in and signed-out feedback

Send feedback

Type of feedback

The page you're on and your device type are attached automatically.